News

New Report Reveals The Extent of Life Science Sector's Perfect Storm

A new report released today by Medicines Discovery Catapult (MDC), in partnership with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry, highlights the impact of recent economic instability on companies in the life sciences sector.

The future health of patients depends on continuing to improve approaches to medicines discovery. However, barriers to investing in companies in the current economic climate threaten to prevent the UK from making some of its biggest breakthroughs.

Salary insights and trends from over 4,000 global professionals across STEM industries

Wondering how your company’s salary offers compare to your competitors? Are you offering above, or below industry standards? Is your business as diverse, inclusive and fair as it should be?

Or are you a STEM professional seeking to uncover salary trends and expectations for your role?

The exclusive insights from our Global STEM report not only offers the answers you're looking for, but also empowers you to make informed decisions for your career or recruitment strategy.

Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis

Innovative nanomedicine company, ViaNautis is the latest biotech to join the impressive line-up at Howard Group’s prestigious Unity Campus

Innovative nanomedicine company, ViaNautis is the latest biotech to join the impressive line-up at Howard Group’s prestigious

Unity Campus

Howard Group continues 2024 leasing success at its fast-growing South Cambridge life science and technology campus.

Cushman & Wakefield - Golden Triangle Report - Q1

Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.

Headlines:

Q4 2023 Take-Up Statistics

- Golden Triangle leasing activity totalled 169,000 sq ft in Q1 2024.

- Whilst a step down from the 364,000 leased in Q4 2023, it remained 5% above the five-year quarterly average.

11 installs successfully completed

Novel platform automates and accelerates protein production, enabling scale-up to mg amount in less than 48 hours

List of institutes includes, University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute

May eNews is Here

Read eNews for May, featuring:

✅ Welcome from Tony Jones, CEO, One Nucleus

✅ It's All About the Money

✅ Life Sciences Training Made Easy: Your New Sat Nav Guide!

✅ The Good Housekeeping Guide to Dealmaking

GMP Compliant Cell Culture Medium Streamlines API Manufacture

AMSBIO has launched an enhanced GMP-compliant version of its animal-origin-free, chemically defined StemFit™ iPSC expansion medium.

StemFit™ Basic04 CT is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Life Sciences Training Made Easy: Your New Sat Nav Guide!

By Monalisa Breazu, Learning & Development Administrator, One Nucleus

Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Cambridge, UK, April 25, 2024, Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics. The next-generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development.

My Account